TriLink BioTechnologies

Maravai LifeSciences subsidiary — world-leading mRNA CDMO supplying CleanCap capping analogs and GMP-grade mRNA to Moderna, BioNTech, and 500+ biotech clients.

Country
United States
Revenue
~$100M
Employees
~500 emp
FDA GMP ISO 9001
Coverage
CNEUUS
genome-engineering
therapeutics-platforms
Regulatorsfdaemanmpa

Verifiable facts

FactValueSource
Founded1996trilinkbiotech.com
Production siteSan Diego, California (multiple campus locations) and Jupiter, Floridainvestors.maravai.com · sdbj.com · trilinkbiotech.com
CapacitymRNA manufacturing capacity from 1g to >100g per batch; 118,000 sq ft manufacturing facility in San Diego; 5,000 sq ft GMP enzyme facility in Jupiter, Floridainvestors.maravai.com · trilinkbiotech.com
CertificationISO 9001:2015 and ICH Q7 compliant quality systemtrilinkbiotech.com
Revenue$119.8 million (for the year ended December 31, 2025)investors.maravai.com · sec.gov

Independent sources: investors.maravai.com · sdbj.com · sec.gov

Technologies
NameClusterRisk
mRNA platforms & LNP deliverytherapeutics-platformsMedium
Prime editinggenome-engineeringHigh

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.